Cell Population Analysis

1. A method of analysis using mass spectrometry and/or ion mobility spectrometry comprising: using a first device to generate smoke, aerosol or vapour from a target in vitro cell line and/or culture medium derived therefrom; adding a matrix to said aerosol, smoke or vapour to dissolve at least some of the analytes within the aerosol, smoke or vapour, wherein said matrix comprises isopropanol; causing the dissolved aerosol, smoke or vapour, or analyte therein, to impact upon a collision surface located within a, or the, vacuum chamber of a mass spectrometer and/or ion mobility spectrometer so as to generate a plurality of analyte ions, wherein the matrix is added prior to the aerosol, smoke or vapour or analyte therein being impacted on a collision surface; mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and analysing said spectrometric data in order to identify and/or characterise said target cell line or one or more cells and/or compounds present in said target cell line and/or culture medium derived therefrom; wherein said cell line comprises or consists of mutant and/or transgenic cells and wherein the cell line is a human or non-human animal cell line.

2. The method as claimed in claim 1 , wherein the step of analysing comprises analysing said spectrometric data in order to analyse one or more of the following: (i) analyse the ability of a cell line to produce a therapeutic substance; (ii) analyse the genotype and/or phenotype of said cell line or one or more cell types present therein; (iii) analyse a process involving said cell line or one or more cell types present therein; (iv) analyse the effect of manipulating the genotype and/or phenotype of said cell line or one or more cell types present therein; (v) analyse the effect of a substance on said cell line or one or more cell types present therein; (vi) analyse the production of a substance; and (vii) analyse the viability of said cell line.

3. The method as claimed in claim 1 , wherein said step of using said first device to generate aerosol, smoke or vapour from one or more regions of the target further comprises irradiating said target with a laser.

4. The method as claimed in claim 1 , wherein said first device comprises or forms part of an ion source selected from the group consisting of: (i) a rapid evaporative ionisation mass spectrometry (“REIMS”) ion source; (ii) a desorption electrospray ionisation (“DESI”) ion source; (iii) a laser desorption ionisation (“LDI”) ion source; (iv) a thermal desorption ion source; (v) a laser diode thermal desorption (“LDTD”) ion source; (vi) a desorption electro-flow focusing (“DEFFI”) ion source; (vii) a dielectric barrier discharge (“DBD”) plasma ion source; (viii) an Atmospheric Solids Analysis Probe (“ASAP”) ion source; (ix) an ultrasonic assisted spray ionisation ion source; (x) an easy ambient sonic-spray ionisation (“EASI”) ion source; (xi) a desorption atmospheric pressure photoionisation (“DAPPI”) ion source; (xii) a paperspray (“PS”) ion source; (xiii) a jet desorption ionisation (“JeDI”) ion source; (xiv) a touch spray (“TS”) ion source; (xv) a nano-DESI ion source; (xvi) a laser ablation electrospray (“LAESI”) ion source; (xvii) a direct analysis in real time (“DART”) ion source; (xviii) a probe electrospray ionisation (“PESI”) ion source; (xix) a solid-probe assisted electrospray ionisation (“SPA-ESI”) ion source; (xx) a cavitron ultrasonic surgical aspirator (“CUSA”) device; (xxi) a hybrid CUSA-diathermy device; (xxii) a focussed or unfocussed ultrasonic ablation device; (xxiii) a hybrid focussed or unfocussed ultrasonic ablation and diathermy device; (xxiv) a microwave resonance device; (xxv) a pulsed plasma RF dissection device; (xxvi) an argon plasma coagulation device; (xxvi) a hybrid pulsed plasma RF dissection and argon plasma coagulation device; (xxvii) a hybrid pulsed plasma RF dissection and JeDI device; (xxviii) a surgical water/saline jet device; (xxix) a hybrid electrosurgery and argon plasma coagulation device; and (xxx) a hybrid argon plasma coagulation and water/saline jet device.

5. The method as claimed in claim 1 , wherein said cell line is identified, confirmed or authenticated as comprising or consisting of mutant and/or transgenic cells on the basis of said spectrometric data.

6. The method as claimed in claim 1 , wherein said method is performed on a cell line in need of authentication, and the method comprises analysing said spectrometric data in order to: (i) confirm the authenticity of the cell line; (ii) detect a mutation in said cell line; or (iii) to detect an undesired variation in said cell line.

7. The method as claimed in claim 1 , wherein said method comprises analysing said spectrometric data in order: (i) to determine whether or not said cell line suffers from an infection; (ii) to determine whether or not said cell line is infection free; (iii) to determine whether or not said cell line has been cured of an infection; (iv) to determine the progression or stage of an infection of a cell line; and/or (v) to determine the progression or stage of a treatment for an infection of a cell line.

8. The method as claimed in claim 1 , wherein said method comprises analysing said spectrometric data in order to analyse the effect of a genotype and/or phenotype manipulation on a cellular process, a disease, drug production by a cell line, and/or the response of a cell line to a substance and/or environmental condition.

9. The method as claimed in claim 1 , wherein said method comprises analysing said spectrometric data in order to analyse the effect of mutagenesis on said cell line.

10. The method as claimed in claim 1 , wherein said method comprises a screening method optionally a high-throughput screening method.

11. The method as claimed in claim 1 , wherein said method is used for drug discovery and/or drug analysis.

12. The method as claimed in claim 1 , wherein said target is a first target sample and said spectrometric data is first spectrometric data and wherein the method further comprises: generating aerosol, smoke or vapour from a second different target sample; mass analysing and/or ion mobility analysing aerosol, smoke or vapour generated from the second target sample, or ions derived therefrom, so as to obtain second spectrometric data; and comparing said first and second spectrometric data to determine differences between said first and the second target samples.

13. The method as claimed in claim 12 , wherein said first cell line comprises a first genetic modification and said second cell line does not comprise said first genetic modification, and said method comprises analysing said first and second spectrometric data to analyse the effect of said first genetic modification.

14. The method as claimed in claim 12 , wherein said first cell line comprises a first genetic modification and said second cell line comprised a second genetic modification, and said method comprises analysing said first and second spectrometric data to analyse the effect of said second genetic modification.

15. An apparatus comprising: a first device for generating smoke, aerosol or vapour from a target in vitro cell line and/or culture medium derived therefrom; a second device configured to add a matrix to said aerosol, smoke or vapour to dissolve at least some of the analytes within the aerosol, smoke or vapour; a collision surface located within a, or the, vacuum chamber of a mass spectrometer and/or ion mobility spectrometer, wherein the apparatus is configured to cause the dissolved aerosol, smoke or vapour, or analyte therein, to impact upon the collision surface so as to generate a plurality of analyte ions, wherein the apparatus is configured such that the matrix is added prior to the aerosol, smoke or vapour or analyte therein being impacted on the collision surface; a mass spectrometer and/or ion mobility spectrometer for analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and a processor adapted to analyse said spectrometric data in order to identify and/or characterise said target cell line or one or more cells and/or compounds present in said target cell line and/or culture medium derived therefrom; wherein said cell line comprises or consists of mutant and/or transgenic cells and wherein the cell line is a human or non-human animal cell line; and wherein said matrix comprises isopropanol; and/or wherein said apparatus comprises a sample transfer tube and a matrix introduction conduit, wherein said apparatus is configured to transfer the aerosol, smoke or vapour into a vacuum chamber of the mass spectrometer and/or ion mobility spectrometer via the sample transfer tube; wherein the apparatus is configured to add the matrix to said aerosol, smoke or vapour via the matrix introduction conduit; wherein the matrix introduction conduit has an inlet for receiving the matrix and an outlet that intersects with the sample transfer tube so as to allow the matrix to be intermixed with the smoke, aerosol or vapour in the sample transfer tube.

16. The apparatus as claimed in claim 15 , wherein said processor is adapted to analyse said spectrometric data in order to: (i) analyse the ability of a cell line to produce a therapeutic substance; (ii) analyse the genotype and/or phenotype of said cell line or one or more cell types present therein; (iii) analyse a process involving said cell line or one or more cell types present therein; (iv) analyse the effect of manipulating the genotype and/or phenotype of said cell line or one or more cell types present therein; (v) analyse the effect of a substance on said cell line or one or more cell types present therein; (vi) analyse the production of a substance; and (vii) analyse the viability of said cell line.

17. A method of analysis using mass spectrometry and/or ion mobility spectrometry comprising: using a first device to generate smoke, aerosol or vapour from a target in vitro cell line and/or culture medium derived therefrom; adding a matrix to said aerosol, smoke or vapour to dissolve at least some of the analytes within the aerosol, smoke or vapour; causing the dissolved aerosol, smoke or vapour, or analyte therein, to impact upon a collision surface located within a, or the, vacuum chamber of a mass spectrometer and/or ion mobility spectrometer so as to generate a plurality of analyte ions, wherein the matrix is added prior to the aerosol, smoke or vapour or analyte therein being impacted on a collision surface; mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and analysing said spectrometric data in order to identify and/or characterise said target cell line or one or more cells and/or compounds present in said target cell line and/or culture medium derived therefrom; wherein said cell line comprises or consists of mutant and/or transgenic cells and wherein the cell line is a human or non-human animal cell line; and wherein said method comprises transferring the aerosol, smoke or vapour into a vacuum chamber of a mass spectrometer and/or ion mobility spectrometer via a sample transfer tube; and adding the matrix to said aerosol, smoke or vapour via a matrix introduction conduit; wherein the matrix introduction conduit has an inlet for receiving the matrix and an outlet that intersects with the sample transfer tube so as to allow the matrix to be intermixed with the smoke, aerosol or vapour in the sample transfer tube.